Hofmann Jörg, Grunert Hans-Peter, Donoso-Mantke Oliver, Zeichhardt Heinz, Kruger Detlev H
National Consultant Laboratory for Hantaviruses, Institute of Medical Virology, Helmut-Ruska-Haus, Charité-University Medicine, Charitéplatz 1, 10117 Berlin, Germany.
GBD Gesellschaft für Biotechnologische Diagnostik mbH, Potsdamer Chaussee 80, 14129 Berlin, Germany.
Int J Med Microbiol. 2015 Oct;305(7):607-11. doi: 10.1016/j.ijmm.2015.08.009. Epub 2015 Aug 21.
Hantavirus infections in Germany appear periodically with peak numbers every 2-3 years. The reported cases in the years 2007, 2010 and 2012 exceeded many times over those in the years in-between. In order to reveal faults of certain in vitro diagnostic assays (IVDs), to harmonize the performances of the individual assays and to improve the users' competence in interpreting the results, the National Consiliary Laboratory for Hantaviruses and INSTAND e.V. (Society for Promoting Quality Assurance in Medical Laboratories e.V.) established an external quality assessment (EQA) scheme for proficiency testing of hantavirus serodiagnostics. The first EQA scheme (pilot study) started in March 2009 with 58 participating laboratories from Germany and neighboring countries. Twice a year four serum samples were sent out to the participants to investigate whether the sample reflects an acute or past infection and to distinguish between infections with the hantavirus types Puumala virus (PUUV) and Dobrava-Belgrade virus (DOBV), both endemic in Central Europe. In addition, samples negative for anti-hantavirus antibodies were tested in order to examine the specificity of the IVDs applied in the participating laboratories. An increasing number of laboratories participated, with a maximum of 92 in March 2014. When summarizing in total 2592 test results, the laboratories reached an overall specificity of 96.7% and a sensitivity of 95% in their detection of a hantavirus infection. A correct distinction between acute and past infections was forwarded in 90-96% of replies of laboratories. Exact serotyping (PUUV vs. DOBV) of the infection was reported in 81-96% of replies with the lowest accuracy for past DOBV infections; cross-reactivities between diagnostic antigens of the two viruses as well as persistent IgM titers in humans may interfere with exact testing. The EQAs revealed acceptable results for the serodiagnostic of hantavirus infection including serotyping but further improvement is still needed.
德国的汉坦病毒感染呈周期性出现,每2至3年出现病例数高峰。2007年、2010年和2012年报告的病例数比其间年份的病例数高出许多倍。为了揭示某些体外诊断检测方法(IVD)的缺陷,协调各检测方法的性能,并提高用户解读结果的能力,国家汉坦病毒参考实验室和德国医学实验室质量保证促进会(INSTAND e.V.)建立了一项用于汉坦病毒血清学诊断能力验证的外部质量评估(EQA)计划。首个EQA计划(试点研究)于2009年3月启动,有来自德国及周边国家的58个参与实验室。每年向参与者发送两次四份血清样本,以调查样本是否反映急性感染或既往感染,并区分由普马拉病毒(PUUV)和多布拉伐-贝尔格莱德病毒(DOBV)这两种在中欧流行的汉坦病毒类型引起的感染。此外,还对抗汉坦病毒抗体阴性的样本进行检测,以检验参与实验室所应用IVD的特异性。参与实验室的数量不断增加,2014年3月最多达到92个。在总计2592个检测结果中,实验室在检测汉坦病毒感染时的总体特异性为96.7%,灵敏度为95%。在实验室90%至96%的回复中能够正确区分急性感染和既往感染。在81%至96%的回复中报告了感染的准确血清型(PUUV与DOBV),既往DOBV感染的准确率最低;两种病毒诊断抗原之间的交叉反应以及人类体内持续的IgM滴度可能会干扰准确检测。EQA显示汉坦病毒感染血清学诊断(包括血清分型)的结果可以接受,但仍需进一步改进。